ORMP News and Press, Oramed Pharmaceuticals Inc. From 11/23/21

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study PR Newswire NEW YORK , Nov. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of ...

Gainers: iSpecimen (NASDAQ:ISPC) +85%. Navitas Semiconductor (NYSE:NVTSW) +29%. Vonage (NASDAQ:VG) +26%. Astra (NASDAQ:ASTR) +25%. Avaya (NYSE:AVYA) +25%. Lee Enterprises (NASDAQ:LEE) +24%. Cloopen Group (NYSE:RAAS) +24%. MultiPlan (NYSE:MPLN) +23%. Partner (NASDAQ:PTNR) +20%. Camber Energy (...

Gainers: iSpecimen (NASDAQ:ISPC) +120%, MultiPlan (NYSE:MPLN) +21%, Provention Bio PRVB +20%, Stoke Therapeutics (NASDAQ:STOK) +16%, Star Equity STRR +14%. Losers: Gracell Biotechnologies (NASDAQ:GRCL) -31%, Aurinia Pharmaceuticals (NASDA...

A new study published in Cell Host and Microbe has indicated that the VXA-A1.1, an experimental oral tablet flu vaccine developed by Vaxart (NASDAQ:VXRT), offered cellular correlates of protection against the infection caused by the influenza virus. In a Phase 2 human challenge...

Oramed Pharmaceuticals (NASDAQ:ORMP) and Genomma Lab Internacional (OTCPK:GNMLF) have formed a 50/50 joint venture to commercialize Oramed's oral COVID-19 vaccine candidate in Mexico. Genomma will provide resources to the vaccine's development, as well as clinical, regulatory, and c...

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America - Millions of people in the region could benefit from the COVID-19 vaccine candidate...

Oramed to Present at H.C. Wainwright 7th Annual Israel Conference PR Newswire NEW YORK , November 11, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the devel...

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules PR Newswire NEW YORK , Nov. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ...

Oramed Pharmaceuticals (ORMP -11.2%) has lost more than a tenth in value after the company announced $50M at the market offering of 2M shares of its common stock. Subject to customary closing conditions, the registered direct offering is expected to take place on about Nov. 05 at a purchase p...

Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules PR Newswire NEW YORK , Nov. 3, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) ( www.or...